Hanx Biopharmaceuticals (Wuhan) Co., Ltd. - B - H Shares (HANXBIO-B, 3378.HK) is listed on HKEX. The latest available quote update was captured at 2026-03-26 10:40:17.0.
Quote Snapshot
- Last Price: 27.640 HKD
- Day Change: -0.640 (-2.26%)
- Open: 28.000 HKD
- High: 28.740 HKD
- Low: 26.500 HKD
- Previous Close: 28.280 HKD
- Volume: 138.80 K
- Market Cap: 3.76 B
- P/E Ratio: N/A
- Dividend Yield: N/A
- Board Lot: 100
- ISIN: CNE100007C34
- Industry: Healthcare - Pharmaceuticals & Biotechnology
Company Overview
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a China-based company mainly engaged in the research and development of immune-oncology therapies. The Company’s product pipeline comprises clinical stage drug candidates focused on oncology and preclinical stage drug candidates, including Core Product HX009 and Key Products HX301 and HX044, as well as antibody drug conjugate, bispecific antibody and monoclonal antibody for both autoimmune and oncology market. HX009 is a bifunctional anti-programmed cell death protein 1 (PD-1) antibody signal regulatory protein α (SIRPα) fusion protein developed in-house. HX301 is a multi-targeted kinase inhibitor targeting critical pathways such as colony-stimulating factor-1 receptor (CSF1R), AMPK-associated protein kinase 5 (ARK5), FMS-like tyrosine kinase 3 (FLT-3), and cell cycle-independent kinase 4/6 (CDK 4/6). HX044 is a novel bifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody SIRPα fusion protein.
Risk & Return Metrics
Based on 61 trading days of close price data (daily returns, annualized using 252 trading days).
| Metric | Daily | Annualized |
|---|---|---|
| Expected Return | 0.9365% | 947.42% |
| Risk (Std Dev) | 4.6385% | 73.63% |
| Metric | Value |
|---|---|
| First Price (HKD) | 17.200 |
| Last Price (HKD) | 28.280 |
| Total Return | 64.42% |